A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease.
- 2025-01-30
- RCT · n = 44
- BMC complementary medicine and therapies 25(1)
- Sara Mighani
- Rasoul Samimi
- Mohamadreza Rashidi Nooshabadi
- Seyed Amir Farzam
- Hossein Khadem Haghighian
- Maryam Javadi
- PubMed: 39885430
- DOI: 10.1186/s12906-025-04759-4
- High evidence
- Clinical
the mean of insulin, insulin resistance (IR), triglycerides (TG), low-density lipoprotein (LDL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), malondialdehyde (MDA), and C-reactive protein (CRP) were significantly decreased in the intervention group (P < 0.05)
- Effect
- Beneficial
- Effect size
- Moderate
- Significant
- Yes
- Dose
- 180 mg per day